

1 **Divergent transcriptomic profiles in depressed individuals with hyper- and hypophagia implicating**
2 **inflammatory status**

3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

Shu Dan^{1,*}, Julia Hall^{2,*}, Laura M. Holsen^{2,3#}, and Torsten Klengel^{1,#}

Affiliations:

¹ Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, MA

² Division of Women’s Health, Department of Medicine, Brigham and Women's Hospital, Boston, MA

³ Department of Psychiatry and Connors Center for Women’s Health and Gender Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

* Denotes equal first author contribution

Denotes equal senior author contribution

Correspondence: Laura Holsen, PhD (lholsen@bwh.harvard.edu, 1620 Tremont Street, BC-3, Boston, MA 02120) and Torsten Klengel, MD, PhD (tklengel@mclean.harvard.edu, McLean Hospital, 115 Mill Street, Belmont, MA 02478)

Word Count

Abstract: 159

Text: 5,224

Figures: 3

Tables: 5

Supplemental Figures: 3

Supplemental Tables: 5

Keywords: appetite, endophenotype, biomarker, stress, eating behavior

34 **Abstract**

35

36 Major Depressive Disorder (MDD) is a heterogenous and etiologically complex disease encompassing a
37 broad spectrum of psychopathology, presumably arising from distinct pathophysiological mechanisms.
38 Divergent appetitive phenotypes including Hyperphagic MDD (characterized by an increased appetite)
39 and Hypophagic MDD (characterized by a decrease in appetite) are important clinical characteristics that
40 are closely related to comorbidities, including cardiometabolic disorders. Prior evidence supports the
41 notion that hyperphagia is associated with atypical depression, decreased stress-hormone signaling, a
42 pro-inflammatory status, hypersomnia, and poorer clinical outcomes. Yet, our understanding of the
43 underlying mechanisms of Hyperphagic and Hypophagic MDD is limited, and knowledge of associated
44 biological correlates of these endophenotypes remain fragmented. We performed an exploratory study
45 on peripheral blood RNA profiling using bulk RNAseq in unmedicated individuals with Hyperphagic and
46 Hypophagic MDD (n=8 and n=13, respectively) and discovered individual genes and gene pathways
47 associated with appetitive phenotypes. In addition, we used the Maastricht Acute Stress Task to uncover
48 stress-related transcriptomic profiles in Hyper- and Hypophagic MDD.

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66 Introduction

67

68 The phenotypic and etiologic heterogeneity in Major Depressive Disorder (MDD) remains a significant
69 challenge toward establishing a better understanding of the underlying molecular mechanisms leading
70 to MDD and in turn more effective and personalized treatments. Differences in appetite and weight are
71 common among depressed individuals, with approximately half experiencing a loss of appetite and
72 about a third of MDD patients exhibiting an increase in appetite¹. An increased appetite along with
73 weight gain is a feature of atypical depression whereas a decrease is commonly associated with
74 melancholic depression. However, despite prior evidence suggesting that changes in appetite and
75 weight are relevant long-term markers of divergent endophenotypes in depression, and although they
76 can be easily assessed, these phenotypes remain understudied².

77

78 Recent data highlight, in part, the neurobiological underpinnings of opposing appetite-related
79 phenotypes of MDD. At the immune and hormone level, depressed individuals with increased appetite
80 show associations with decreased HPA axis activation¹, increased inflammation³, and insulin resistance¹,
81 while those with decreased appetite exhibit elevated ghrelin secretion in response to a meal⁴. At the
82 neural systems level, there is initial evidence of hyperactivity in ventral striatum, pallidum, and putamen
83 among Hyperphagic MDD subjects in response to food cues, and attenuated activation in the insula in
84 Hypophagic MDD⁵. During rest, there is evidence of aberrant and divergent connectivity between
85 nucleus accumbens, medial prefrontal cortex, insula, and orbitofrontal cortex in these groups compared
86 to healthy controls^{6,7}. Moreover, we and others have noted associations between activation to food
87 cues and hormone (including ghrelin and cortisol) and immune (CRP, IL-1RA, IL-6) markers, in opposing
88 directions for Hyper- and Hypophagic MDD^{1,4,8}. Taken together, these findings converge to suggest
89 distinct associations between immunometabolic and hormone markers and broad reward and
90 interoceptive network aberrations that track with divergent appetitive phenotypes of MDD. However,
91 few studies have examined the molecular basis underlying appetitive and stress responsivity in Hyper-
92 and Hypophagic MDD, which could play a critical role in the development and maintenance of appetite
93 increases and decreases in MDD.

94

95 Molecular analyses of individuals with Hyperphagic and Hypophagic MDD provide further evidence for
96 genetic⁹ and transcriptional¹⁰ differences. An early transcriptomic study in n=1212 individuals (n=331
97 healthy controls, n=246 hyperphagia, and n=341 hypophagia) by de Kluiver et al revealed transcriptomic

98 changes in line with an increased inflammatory status in Hyperphagic MDD compared to controls. This
99 pro-inflammatory phenotype was strongly attenuated in Hypophagic MDD vs. controls. De Kluiver et al
100 concluded that hyperphagia represents a distinct depressive subtype with partly differential
101 pathophysiology regarding immune-metabolic processes that may benefit from more personalized anti-
102 inflammatory treatment strategies. While de Kluiver emphasized the importance of the Hyperphagic
103 subtype of MDD, we hypothesized that contrasting hyper- and hypophagia directly in an unbiased way
104 using RNAseq would allow us to uncover additional transcriptional profiles that disentangle both
105 phenotypes. In addition, considering the critical role of stress in appetitive function and in the
106 pathophysiology of MDD, we introduced the Maastricht Acute Stress Test (MAST) which elicits a strong
107 autonomic and glucocorticoid stress response, to uncover additional stress-related transcriptomic
108 changes as a function of hyper- and hypophagia.

109

110 **Methods**

111

112 *Participants*

113

114 As part of a larger study on the relationship between stress and hormone function in MDD, adults with
115 Major Depressive Disorder and healthy controls without current psychiatric disorders 21 and 45 years of
116 age and with a BMI between 19 and 45 kg/m² were recruited from the greater Boston area through
117 online advertisements. From the larger sample of participants who completed all study components,
118 RNA samples for the current analyses were collected on a subset of 21 individuals with Hyperphagic and
119 Hypophagic MDD (8 Hyperphagic MDD [5 female]; 13 Hypophagic MDD [7 female]). Exclusion criteria
120 included the history of substance abuse; current comorbid psychiatric disorders; current psychotropic
121 medications use; history of neurological disease; endocrine disorders; diabetes; cardiovascular disease;
122 current treatment with weight loss medications; glucocorticoids; steroids; current suicidal ideation;
123 traumatic brain injury; for females, pregnancy or breastfeeding, and past amenorrhea greater than
124 three months. All participants with MDD met diagnostic criteria as assessed by the Structured Clinical
125 Interview for Diagnoses (SCID; DSM-IV-TR)¹¹ administered by a trained clinician interviewer with over 20
126 years of experience. Participants with MDD were assigned into Hyperphagic MDD (e.g., increased
127 appetite/weight gain) and Hypophagic MDD (e.g., decreased appetite/weight loss) groups based on their
128 responses to appetite- and weight-related assessment in the mood disorders module of the SCID.
129 Specifically, MDD group was assigned based on responses to criterion Question A3 under the “A. Mood

130 Episodes” module: “(3) significant weight loss when not dieting, or weight gain (e.g., a change of more
131 than 5% body weight in a month) or decrease or increase in appetite nearly every day for the past 2
132 weeks”. Participants who endorsed either weight loss OR decrease in appetite nearly every day for 2
133 weeks (A4) were categorized as Hypophagic MDD. Participants who endorsed either weight gain OR
134 increase in appetite nearly every day for 2 weeks over the past month (A5) were categorized as
135 Hyperphagic MDD. All participants provided written informed consent. All study procedures were
136 approved by the Mass General Brigham Institutional Review Board.

137

138 *Procedures*

139

140 Following a screening session to establish MDD status and obtain height, weight, anthropometric
141 measurements, and hematocrit level (<34% in females and <37% in males), eligible participants
142 underwent two main study visits (1 week apart) that were identical except one included a stress-
143 inducing version (Stress) and the other included a non-stressful control version (No Stress) of the
144 Maastricht Acute Stress Task (MAST)¹². Visit order (Stress, No Stress) was randomized and
145 counterbalanced across groups. Visits occurred between 0800 hrs and 1300 hrs following a 12-hour
146 overnight fast. For females, all visits occurred during the follicular phase of the menstrual cycle. Upon
147 arrival, participants completed the Beck Depression Inventory (BDI-II) to assess current depressive
148 symptoms¹³; female participants underwent a pregnancy test. Next, a nurse placed an intravenous
149 catheter (IV) with a saline lock for blood sampling. After the IV was placed, participants consumed a
150 breakfast meal (within a 15-minute period to standardize rate of intake) designed to comprise 30% of
151 their recommended daily caloric intake (see detailed description below). The T0 blood draw was
152 completed immediately following the breakfast session. At this time, participants completed an
153 assessment of their mood using an electronic visual analog scale (VAS) system¹⁴.

154

155 Participants then completed either the Stress or No-Stress version of the MAST. Participants were
156 seated in front of a computer, and a water bath was positioned on the side of the arm that did not have
157 the IV. Participants were then introduced to a female experimenter posing as a doctor who provided
158 detailed instructions for the water and math task. This was followed by 10 minutes during which the
159 participants alternated between five hand immersion trials (60 sec to 90 sec) and four arithmetic trials
160 (30 sec to 90 sec). During the task, trial switching was prompted by a timed slideshow running on the
161 computer (**Figure 1**).

162

163 During the Stress visit, hand immersion trials required the participant to place their hand and wrist in
164 cold water that was held between 0°C and 2°C. Arithmetic trials required counting backward as quickly
165 and accurately as possible from 2,043 in intervals of 17. If a mistake was made, the experimenter
166 instructed the participant to start again from 2,043. Participants were told their performance was being
167 videotaped by a camera that was mounted to the computer screen. In reality, the camera was not
168 recording. Following the final hand immersion trial, participants were told that their performance was
169 poor and that they would need to repeat the task later during the visit; this manipulation was used to
170 induce sustained levels of stress throughout the visit.

171

172 During the No-Stress visit, the water temperature was lukewarm (25°C – 37°C), and the math trials
173 required counting up consecutively from 1 to 25 in steps of 1 at their own pace and starting over once
174 they reached 25. There was no mention of videotaping, and the experimenter gave no feedback on their
175 performance. The study staff member playing the role as doctor was consistent for each participant
176 across Stress and No-Stress visits.

177

178 Approximately 85 minutes after the MAST (105 minutes since T0), a second sample of blood was drawn
179 while participants completed a second mood assessment via the VAS system. At the end of each visit,
180 participants were fully debriefed. During the No-Stress visit, participants completed a questionnaire
181 packet including the trait portion of the State-Trait Anxiety Inventory (STAI)¹⁵, Perceived Stress Scale
182 (PSS)¹⁶, and the Dutch Eating Behavior Questionnaire (DEBQ)¹⁷.

183

184 *Anthropometry*

185

186 At the screening visit, height (cm) and weight (kg) were measured using a stadiometer. Those values
187 were used to calculate body mass index (BMI [kg/m²]).

188

189 *Breakfast meal*

190

191 At the start of each visit, participants ate a breakfast meal that was standardized to meet 30% of their
192 daily caloric intake. Breakfast was prepared by Center for Clinical Investigation (CCI) dietary staff at
193 Brigham and Women's Hospital and varied according to each participant's basal metabolic rate and

194 physical activity level, measured by the Harris-Benedict equation with 18% calories from protein, 23%
195 calories from fat, and 59% calories from carbohydrates¹⁸. Participants were encouraged to consume as
196 much of the meal that they could in 15 minutes. After the 15-minute period, CCI dietary staff weighed
197 the remaining food items to determine nutrient intake for total kcals and kcals per macronutrient.
198 Planned versus consumed (PVC) kcals for total breakfast meal and then each individual macronutrient
199 (protein, fat, and carbohydrate) was calculated by dividing the intake values by the planned
200 standardized amounts.

201

202 *Blood sampling, hormone measurement, and RNA processing*

203

204 Blood was sampled at three time points at each visit. Serum cortisol, acylated ghrelin, and RNA were
205 collected at two time points: T0: After the breakfast meal/before the MAST and T105: 105 minutes after
206 T0. Serum cortisol, alone, was collected at T20 as a manipulation check for the effect of the MAST.

207

208 For cortisol, after transferring to a tube containing pefabloc, serum was frozen until assayed. Serum
209 samples for cortisol and ghrelin were stored at -80°C in plastic tubes containing a 10-mg/ml solution of
210 PMSF (phenylmethanesulfonyl fluoride) in methanol. Cortisol samples were assayed by LabCorp (Raritan,
211 NJ) using electrochemiluminescence immunoassay (ECLIA) on a Roche Cobas analyzer; intra-assay CV
212 1.0-1.7%; inter-assay CV 1.4-2.2%.

213

214 Acylated ghrelin was collected in Ethylenediaminetetraacetic acid (EDTA) tubes, aliquoted with HCL, and
215 then centrifuged. Ghrelin samples were assayed by the Brigham Research Assay Core (BRAC) using an
216 enzyme immunoassay (ELISA; Millipore, St. Charles, MO; intra-assay CV 0.8-7.5%; inter-assay CV
217 3.9=12.9%).

218

219 Total RNA was collected in Tempus Blood RNA tubes (Thermo Fisher Scientific, Waltham, MA) incubated
220 at room temperature for 2 hours and stored at -80°C according to the instructions of the manufacturer
221 until further processing. Total RNA was extracted using the Norgen Total RNA Purification Kit (Cat.
222 17200, Norgen Biotek Corp, Thorold, ON, Canada) and quantified using a Qubit 2.0 Fluorometer (Thermo
223 Fisher Scientific Inc., Waltham, MA). All samples were run on an Agilent 2100 Bioanalyzer (Agilent,
224 Technologies, Santa Clara, CA) to determine RNA Integrity Number (RIN) and all samples passed QC with
225 RIN values >6 (mean = 8.81, SD = 0.46).

226

227 *Behavioral measures*

228

229 *Beck Depression Inventory (BDI-II)* – The BDI-II is a 21-item self-report questionnaire used to assess
230 presence and severity of depressive symptoms¹³. Each item presents a characteristic (e.g., ‘Self-Dislike’)
231 with four statements below it (labeled 0, 1, 2, and 3), with 0 representing minimal change in/severity of,
232 and 3 representing maximal change in/severity of that characteristic. Participants were asked to indicate
233 to what extent they experienced that characteristic in the past two weeks by choosing the statement
234 they agreed with. Scores were calculated by summing the answers to each question. Higher scores
235 indicate more severe depressive symptoms.

236

237 *Mood Assessment* – Ratings of sadness and tension were measured during the T0 and T105 blood draws
238 using an electronic visual analog scale (VAS) system¹⁴. Participants were asked to rate how sad and how
239 tense they felt by moving a slider on a linear scale that went from 0 to 100, with 0 being the least
240 sad/tense they have ever felt and 100 being the saddest/tensest they have ever felt.

241

242 *Dutch Eating Behavior Questionnaire (DEBQ)* – During the No-Stress visit, participants completed the
243 DEBQ, a 33-item self-report questionnaire that assesses three eating behavior domains: Restrained
244 Eating (10 items), Emotional Eating (13 items), and External Eating (10 items)¹⁷. All items are rated on a
245 5-point scale with responses that range from 1 (‘Never’) to 5 (‘Very Often’). Scores for each subscale
246 were calculated by adding up the item responses within a subscale and then dividing by the number of
247 questions in that subscale resulting in a final score per subscale. Higher scores indicate greater tendency
248 to display the subscale behavior.

249

250 *State-Trait Anxiety Inventory-Trait (STAI-T)* – Trait-based characteristics relating to general anxiety level
251 were assessed using the STAI-T¹⁵. The STAI is comprised of 20 item that ask participants to rate level of
252 proneness to anxiety (e.g., general states of calmness, security, or inadequacy) through Likert scale
253 responses that range from 1 (‘Almost Never’) to 4 (‘Almost Always’). Scoring was reversed for the
254 anxiety-absent items, which comprised 9 of the 20 questions. Total scores were calculated by adding the
255 responses after reverse-scoring. The range of scores is from 20-80, with higher scores indicating greater
256 general anxiety.

257

258 *Perceived Stress Scale (PSS)* – Participants completed the PSS as part of the post-visit questionnaire
259 packet. The PSS is a 10-item questionnaire that assesses how often respondents have felt a particular
260 way in relation to stressful situations within the past month (e.g., ‘In the last month, how often have you
261 been upset because of something that happened unexpectedly?’)¹⁶. Each item is rated on a 5-point
262 Likert-scale, with 0 being never and 4 being very often. Six of the items indicating last of perceived stress
263 were reverse-scored. Total scores were calculated by summing the answers to all the scored and
264 reverse-scored items. Higher scored correspond with higher perceived stress.

265

266 Statistical Methods

267

268 Demographic data, questionnaires, and hormone levels were analyzed using SPSS version 28 (IBM Corp.,
269 2021). The p-value threshold for significance was 0.05. Based on small sample sizes and non-normal
270 distributions, non-parametric statistical tests were employed, and serum cortisol and acylated ghrelin
271 were log₂ transformed. Demographics, baseline characteristics, BDI-II, STAI-T, DEBQ, PSS, and breakfast
272 meal values (PVC total, PVC protein, PVC fat, and PVC carbohydrate) were assessed using Fisher’s Exact
273 Tests, χ^2 , and Mann-Whitney U tests. Within group comparisons in hormone levels and VAS ratings of
274 sadness and tension were assessed using Wilcoxon Signed Rank tests. Between-subjects effects in
275 breakfast intake, cortisol and acylated ghrelin samples, and VAS ratings of sadness and tension were
276 analyzed using Mann-Whitney U tests.

277

278 *Bulk RNA-seq Analysis*

279

280 Total RNA was sent to Genewiz (Azenta Life Sciences, Burlington, MA) for bulk-RNAseq. All samples were
281 treated with TURBO DNase (Thermo Fisher Scientific, Waltham, MA) to remove residual DNA
282 contaminants. Ribosomal RNA and globin RNA was depleted using QIAseq FastSelect–rRNA HMR and
283 –Globin kit (Qiagen, Germantown, MD). RNA sequencing libraries were constructed with the NEBNext
284 Ultra II RNA Library Preparation Kit for Illumina. The sequencing libraries were multiplexed and clustered
285 on seven lanes of a flowcell. After clustering, the flowcell was loaded on the Illumina HiSeq 4000
286 instrument according to manufacturer’s instructions. The samples were sequenced using a 2x150 Pair-
287 End (PE) configuration. Image analysis and base calling were conducted by the HiSeq Control Software
288 (HCS). Raw sequence data (.bcl files) generated from Illumina HiSeq was converted into FASTQ files and
289 de-multiplexed using Illumina's bcl2fastq 2.17 software. One mismatch was allowed for index sequence

290 identification. The obtained RNAseq data was processed through the bulk RNA-seq pipeline in bcbio
291 (v1.2.8)¹⁹. Reads were aligned using STAR against transcriptome references of the human genome
292 (GRCh38 Ensembl release 94)²⁰ and quantified with Salmon²¹. Two samples were excluded in further
293 analysis due to poor sequencing quality.

294

295 *Differential Gene Expression Analysis*

296

297 Differential gene expression analysis was performed using limma (v3.46.0)²². Counts were filtered using
298 `limma::filterByExpr` with default settings. Counts from both time points were normalized with
299 `limma::voom` and repeated measures from same individual were accounted for using
300 `limma::duplicateCorrelation`. To determine which covariates to include in the final analysis, association
301 tests were performed between all known variables (group [Hyperphagic MDD, Hypophagic MDD], visit
302 [Stress, No-Stress], sequencing quality metrics [percent_gc, r_rna, r_rna_rate, intergenic_rate,
303 intronic_rate, exonic_rate, duplication_rate_of_mapped, average_insert_size, total_reads,
304 mapped_reads, mapped_paired_reads, duplicates_pct], individual, sex, age, BMI, visit, breakfast intake
305 [bfast_pvc_TOT, bfast_pvcPROT, bfast_pvcFAT, bfast_pvcCARB], RIN, RNA_extraction_batch) and the 12
306 calculated principal components (PCs) for each timepoint separately. Some sequencing metrics, RIN,
307 RNA extraction batch, and breakfast intake tested, did not show a significant association with the top
308 PCs (**Supplemental Figure 1**). However, sequencing quality related metrics (intergenic_rate,
309 intronic_rate, exonic_rate, duplication_rate_of_mapped, average_insert_size, and duplicates_pct)
310 showed a significant association with the variation in our data as captured in the top PC and therefore
311 exonic rate was included in the downstream models ($p_{\text{Bonferroni}} < 0.05$). Other sequencing related metrics
312 were not included due to their correlation with exonic rate to prevent collinearity in the model.

313

314 At baseline T0, the gene expression differences between Hyperphagic MDD and Hypophagic MDD
315 groups were compared using a linear mixed model controlling for age, BMI, sex, calories of breakfast
316 intake, sequencing quality, and repeated measures. At T105, the gene expression differences between
317 Hyperphagic MDD and Hypophagic MDD groups under stress were compared using a linear mixed model
318 with group and visit interaction terms controlling for age, BMI, sex, calories of breakfast intake,
319 sequencing quality, and repeated measures. Nominal p-values from both models were adjusted for
320 inflation with `bacon` (v1.18.0)²³ and differentially expressed genes were considered significant at
321 $p_{\text{FDR}} < 0.05$.

322

323 Normalized counts of all significant genes identified at both time points were tested for correlation with
324 corresponding cortisol and ghrelin levels, breakfast PVC values and mood ratings in linear regression
325 models controlling for sex and repeated measures. Normalized counts at T0 were then averaged
326 between visits to test for association with corresponding DEBQ subscale scores in linear regression
327 models controlling for sex.

328

329 *Enrichment Analysis*

330

331 Differentially expressed genes (DEGs) identified at nominal significance level were used in the
332 enrichment analyses. Overrepresentation tests were used to determine the enrichment of Gene
333 Ontology (GO) terms^{24,25}. All genes were ranked based on log fold change and used as input for Gene Set
334 Enrichment Analysis (GSEA) to assess the level of enrichment of 161 inflammatory pathways identified
335 by de Kluiver et al¹⁰ that are available from the Human MSigDB Gene Set^{26,27}. The pathway “Reactome
336 RIGI MDA5 mediated induction of IFN alpha beta pathway” was not found in the Human MSigDB Gene
337 Sets database and excluded in the GSEA analysis.

338

339

340 *Data and Code Availability*

341

342 All RNA-seq statistical analyses were performed in R software version 4.0.2. Bulk RNA-seq data can be
343 accessed through GEO Accession GSE231347. Code used in the analysis has been deposited on Github:
344 <https://github.com/klengellab/HypoHyperMDD> .

345

346 **Results**

347

348 *Demographic and Trait Characteristics*

349

350 Direct comparison between Hyperphagic MDD and Hypophagic MDD revealed that groups did not differ
351 in demographic characteristics (sex [$p=1.000$], age [$z=-0.545$, $p=0.595$], BMI [$z=-0.072$, $p=0.972$], race
352 [$p=0.118$], ethnicity [$p=0.618$]), or trait-level anxiety/stress-related characteristics (STAI-T [$z=-1.56$,
353 $p=0.121$], PSS [$z=-1.38$, $p=0.185$]) (**Table 1**). Groups differed in self-reported depression symptom

354 severity (BDI-II), with Hyperphagic MDD exhibiting more severe depression symptoms ($z=2.24$, $p=0.025$).
355 There was a significant difference between groups in Emotional Eating ($z=-2.62$, $p=0.008$) and External
356 Eating ($z=-2.04$, $p=0.045$) subscales of the DEBQ, with Hyperphagic MDD exhibiting elevated levels of
357 emotional and external eating behavior compared to Hypophagic MDD. There were no differences
358 between groups in the Restrained Eating subscale ($z=-1.16$, $p=0.268$). For breakfast meal intake,
359 Hyperphagic MDD displayed higher PVC kcals from protein ($z=2.14$, $p=0.030$) compared with Hypophagic
360 MDD. Groups did not differ in PVC total kcals ($z=1.85$, $p=0.064$), PVC kcals from fat ($z=1.78$, $p=0.076$), or
361 PVC kcals from carbohydrates ($z=1.41$, $p=0.161$).

362

363 *Acute effect of MAST on cortisol levels*

364

365 To assess the acute physiological response to stress, cortisol was measured and analyzed at T0 and T20.
366 At the No-Stress visit, there were no significant acute changes in log₂ cortisol from T0 to T20 for either
367 the Hyperphagic MDD group ($z=0.338$, $p=0.735$) or Hypophagic MDD group ($z=1.818$, $p=0.069$). At the
368 Stress visit, an increase in log₂ cortisol from T0 to T20 was observed for the Hyperphagic MDD group
369 ($z=2.197$, $p=0.028$), but not for the Hypophagic MDD group ($z=0.070$, $p=0.944$)

370

371 *Cortisol and Ghrelin Responses*

372

373 Wilcoxon Signed Rank tests were used to assess the within-group effect of time in each group at the
374 Stress and No-Stress visits (**Table 2**). Log₂ cortisol was significantly higher at T0 vs T105 in both
375 Hypophagic MDD ($z=-2.71$, $p=0.006$) and Hyperphagic MDD ($z=-2.24$, $p=0.025$) at the No-Stress Visit.
376 During the Stress visit, log₂ cortisol was significantly elevated at T0 vs. T105 in Hypophagic MDD only
377 ($z=-2.06$, $p=0.039$), with no significant change in Hyperphagic MDD ($z=1.35$, $p=0.176$). There was not a
378 within-subject effect of time on log₂ ghrelin in either group or at either visit (No-Stress Hypophagic MDD
379 [$z=-1.78$, $p=0.075$], No-Stress Hyperphagic MDD [$z=-0.42$, $p=0.674$], Stress Hypophagic MDD [$z=-1.22$,
380 $p=0.221$], Stress Hyperphagic MDD [$z=-1.26$, $p=0.208$]).

381

382 Mann-Whitney U tests were used to compare serum levels of cortisol and acylated ghrelin between
383 groups at the Stress and No-Stress visits (**Table 2**). There were no significant differences found in log₂
384 cortisol at T0, log₂ cortisol at T105, log₂ acylated ghrelin at T0, or log₂ acylated ghrelin at T105 between
385 Hyperphagic MDD and Hypophagic MDD at either the Stress or No-Stress visits.

386 *Mood Ratings*

387
388 Mood was assessed by comparing ratings of tension and sadness between Hyperphagic MDD and
389 Hypophagic MDD at T0 and T105 for each visit (**Table 3**). Within-subject analyses revealed an effect of
390 time on ratings of tension in Hyperphagic MDD at the Stress visit ($z=2.10$, $p=0.035$). There were no other
391 within-subjects effects of time on sadness (No-Stress Hypophagic MDD [$z=-1.07$, $p=0.286$], No-Stress
392 Hyperphagic MDD [$z=0.676$, $p=0.499$], Stress Hypophagic MDD [$z=-1.16$, $p=0.248$], Stress Hyperphagic
393 MDD [$z=-.508$, $p=0.611$] or tension (No-Stress Hypophagic MDD [$z=0.711$, $p=0.477$], No-Stress
394 Hyperphagic MDD [$z=1.47$, $p=0.141$], Stress Hypophagic [$z=0.157$, $p=0.875$]). Between-subjects analyses
395 revealed that Hyperphagic MDD reported feeling significantly more tense than Hypophagic MDD at T105
396 in both the Stress ($z=-1.98$, $p=0.047$) and No-Stress Visit ($z=-2.051$, $p=0.045$). There were no additional
397 differences found between groups in ratings of sadness or tension at either visit.

398
399 *Baseline Transcriptomic Differences*

400
401 At baseline T0 when controlling for age, BMI, sex, calories of breakfast intake, sequencing quality, and
402 repeated measures, the expression of transcriptional adaptor 2-beta (*TADA2B*) gene was significantly
403 increased in the Hyperphagic MDD group in comparison to the Hypophagic MDD group after controlling
404 for multiple testing ($\log_{2}FC=0.22$, $p_{FDR}=0.013$) (**Figure 2A**, QQ-plot in **Supplemental Figure 2**, full list of
405 nominal significant DEGs in **Supplemental Table 1**). The expression of *TADA2B* was positively associated
406 with the DEBQ external eating scores ($\beta=0.107$, $p=0.024$) and PVC fat ($\beta=0.0017$, $p=0.025$) (**Table 4**).
407 However, no significant associations of *TADA2B* expression with \log_{2} cortisol, \log_{2} ghrelin, mood ratings,
408 other DEBQ subscales or breakfast intake were detected.

409
410 72 significantly enriched Gene Ontologies (GO) terms were found based on the nominal significant
411 differentially expressed genes ($p_{nominal}<0.05$, $n=1556$). The top 10 GO terms fall exclusively under the
412 biological processes sub-category relating to inflammation pathways, including the regulation of antigen
413 receptor-mediated signaling pathway, immune response-regulating signaling pathway, and T cell
414 activation pathway ($p_{FDR}<0.05$, $q\text{-value}<0.05$) (**Figure 2B**, **Supplemental Table 2**).

415
416 De Kluiver et al¹⁰ previously described an enrichment of inflammatory pathways in Hyperphagic MDD
417 and -to a lesser extent- Hypophagic MDD relative to healthy individuals. While replicating findings from

418 de Kluiver et al, 8 previously described inflammation-related pathways ($p_{FDR} < 0.1$, q-value < 0.1) were
419 significantly enriched in the Hyperphagic versus Hypophagic group comparison in our study
420 (**Supplemental Table 5**). Among these enriched inflammatory pathways, KEGG T cell receptor signaling
421 was also found to be significantly enriched in the combined MDD and Hyperphagic MDD groups in the
422 de Kluiver et al study ($p_{FDR} < 0.05$).

423

424 *Differential Gene Expression Response to the Maastricht Acute Stress Task*

425

426 A defined stressor may unmask additional stress-responsive differences on the level of RNA expression
427 between Hyperphagic MDD and Hypophagic MDD. In fact, RNAseq profiling 85 minutes after the MAST
428 revealed a subtype-specific differential response of Coiled-Coil Domain Containing 196 (*CCDC196*) (\log_{FC}
429 = 2.10, $p_{FDR} = 0.00063$) and Spermatogenesis Associated 33 (*SPATA33*) ($\log_{FC} = -0.87$, $p_{FDR} = 0.0495$)
430 significantly differentially expressed between Hyperphagic MDD and Hypophagic MDD (**Figure 3A-B**, QQ-
431 plot in **Supplemental Figure 3**, full list of nominal significant DEGs in **Supplemental Table 3**). The
432 expression of *CCDC196* decreased in the Hypophagic MDD group after stress, while increasing in the
433 Hyperphagic MDD group after stress. *CCDC196* expression was also positively associated with PVC
434 protein consumed during breakfast ($\beta = 0.0075$, $p = 0.007$). Conversely, the expression of *SPATA33*
435 increased in the Hypophagic MDD and decreased in the Hyperphagic MDD group after stress. Beyond
436 group differences, the expression of *SPATA33* was negatively associated with stress-induced cortisol
437 changes ($\beta = -0.54$, $p = 0.0050$) and positively associated with PVC protein consumed during breakfast (β
438 = 0.012, $p = 0.049$) (**Table 5**).

439

440 Similar to baseline, Gene Ontology enrichment analyses on nominal significant DEGs ($p_{nominal} < 0.05$, $n =$
441 1296) suggested 6 significantly enriched GO terms that are all ribosomal activity relevant cellular
442 component sub-ontologies ($p_{FDR} < 0.05$, q-value < 0.05) (**Figure 3C**, **Supplemental Table 4**). The
443 differential stress-induced gene set was not enriched in any previously described inflammatory
444 pathways from de Kluiver et al.

445

446 **Discussion**

447

448 Eating behaviors are important endophenotypes of MDD and despite their rather simple assessment,
449 they remain understudied although appetite and weight are critical determinants of therapy response²⁸,

450 medication side effects, and comorbidities²⁹. Prior studies including our work provided evidence for
451 distinct neural networks involved in Hyper- and Hypophagic MDD, with hyperresponsivity and
452 connectivity in Hyperphagic MDD in reward circuits and hypofunctioning within interoceptive circuits in
453 Hypophagic MDD. Molecular, genetic, endocrine, and metabolic studies of hyper- and hypophagia in
454 MDD suggest that appetite, weight gain, obesity and treatment response are intertwined at the level of
455 stress-hormone and orexigenic signaling, immune-metabolic changes, and genetic disposition. Only one
456 study by de Kluiver et al so far investigated the biological correlates of Hyper- and Hypophagic MDD at
457 the level of gene expression in peripheral blood using gene expression arrays. Our study aimed to
458 replicate and expand prior work and to perform a deep phenotyping of hyper- and hypophagia in
459 unmedicated MDD patients and to analyze their differential transcriptomic profile changes in response
460 to stress using RNAseq.

461
462 In line with the handful of prior reports detailing demographic and clinical characteristics of appetite and
463 weight phenotypes in MDD, this small sample of unmedicated individuals with Hyper- and Hypophagic
464 MDD had similar BMIs and endorsed comparable levels of general anxiety and perceived stress. Notably,
465 however, in contrast to our prior report on women with *remitted* MDD, in whom scores on depressive
466 symptomatology and domains of eating behavior (disinhibition, restraint, hunger) were similar for
467 opposing appetitive subgroups, those with Hyperphagic MDD in the current mixed-sex sample reported
468 elevated severity of depressive symptoms and of emotional and external eating than the Hypophagic
469 MDD group⁴. This suggests that, among those with Hyperphagic MDD, (1) depressive symptoms may be
470 more severe; and (2) eating behavior domains may vary with current state, such that internal and
471 external influences on eating characteristics become more pronounced during depressive episodes.

472
473 Moreover, although raw levels of baseline cortisol and ghrelin appeared higher in the Hypophagic MDD
474 group, similar to prior findings¹, comparison of log-transformed values yielded no significant group
475 differences. This may have been due to small sample sizes in each group attenuating statistical power to
476 detect effects. Finally, we noted that based on within-group comparisons of T0 vs. T105 timepoints, the
477 Hyperphagic MDD exhibited a sustained cortisol response to stress that was absent in the Hypophagic
478 MDD group. This effect appeared to be mirrored in ratings of tension, which remained elevated at T105
479 in the Hyperphagic MDD group. To our knowledge, this is the first study to employ a stress manipulation
480 to examine mood and hormone changes to psychosocial stress in opposing appetite/weight phenotypes
481 in MDD.

482

483 To identify biological correlates related to the divergent appetite-related phenotypes described, we
484 performed an unbiased RNAseq study at baseline and after exposure to a defined stressor. At baseline,
485 after the intake of a standardized breakfast meal (T0), the expression of *TADA2B* (Transcriptional
486 Adaptor 2B) differentiates Hyper- and Hypophagic individuals with MDD with higher expression levels in
487 hyperphagia when controlling for relevant covariates (**Figure 2A**). *TADA2B* is a protein coding gene that
488 participates histone acetylation and chromatin remodeling. It has been described primarily in the
489 context of stem cell biology and transcriptional regulation^{30,31}. However, evidence for a role of *TADA2B*
490 in psychiatric disorders is limited to a potential involvement in autism spectrum disorder³², and to the
491 best of our knowledge, *TADA2B* has not been described in the context of MDD or eating disorders. In the
492 pathway analysis of the gene expression signature at baseline, we observed significant enrichment of
493 immune-related gene ontologies in Hyperphagic MDD, suggesting a potential differentiation between
494 these sub-phenotypes based on variations in immune signaling. This finding was reinforced by the
495 overlap identified through GSEA against curated immune pathways established by de Kluiver et al.,
496 replicating aspects of prior studies and providing further evidence of disrupted immune signaling as a
497 hallmark of divergent appetitive phenotypes in MDD.

498

499 As discussed before, HPA axis signaling has been investigated extensively in the context of MDD.
500 Evidence suggests that differences in cortisol levels and HPA axis responsivity may differentiate
501 subgroups of individuals with MDD, particularly in individuals with vegetative symptoms including
502 changes in appetite³³. We applied the Maastricht Acute Stress Task (MAST) in association with RNAseq
503 profiling to uncover stress-induced transcriptional changes in depressed individuals with Hyper- and
504 Hypophagia. Differential gene expression analysis revealed that *CCDC196* (Coiled-Coil Domain
505 Containing 196) and *SPATA33* (Spermatogenesis Associated 33) are differentially expressed between
506 Hyper- and Hypophagia after the MAST. These two novel stress induced transcripts have not been
507 described in the context of psychiatric diseases. *CCDC196*, also known as Long Intergenic Non-Protein
508 Coding RNA 238 (*LINC00238*), encodes a coiled-coil domain-containing (CCDC) protein. CCDC proteins
509 are expressed in various tissue types, particularly in the human reproductive system, and have been
510 identified in the pathological process of migration, proliferation, and metastasis of cancers³⁴. Lower
511 expression of *LINC00238* has been associated with liver cancer and the overexpression of *LINC00238* has
512 been confirmed to act as a tumor suppressor through miR-522 in liver cancer tissues^{35,36}. *SPATA33* is
513 mainly expressed in the human reproductive system and participates in spermatogenesis^{37,38}. It has also

514 been associated with melanoma risk³⁹ and although *SPATA33* has not been extensively studied in
515 neuropsychiatric disease, Liu et al provided evidence on the expression of hypothalamic *SPATA33*
516 changes in response to different calorie restriction interventions in mice⁴⁰. This finding indicates a
517 potential role of *SPATA33* in metabolic regulation of hunger. However, further studies are needed to
518 investigate the mechanism of these specific genes and establish additional evidence for their potential
519 role as biomarkers of Hypophagic and Hyperphagic MDD.

520

521 There are several limitations in the current study. Given the small sample sizes, additional data is
522 required to examine responsivity to psychosocial stress in larger samples of individuals with Hyper- and
523 Hypophagic MDD. Additionally, despite stringent statistical methods of all gene expression analyses, an
524 independent replication in a larger cohort is warranted. In addition, our sample consisted primarily of
525 individuals with Caucasian decent thus future studies need to include a more diverse study population.
526 Even though limitations may narrow the generalizability of this study, we replicate prior work and
527 importantly, provide additional phenotypic and molecular data on unmedicated individuals with
528 Hyperphagic and Hypophagic MDD.

529

530

531

532

533

534

535

536

537

538

539

540 **Author contributions**

541 TK and LMH designed research; TK, LMH, SD, JH conducted research; SD, TK, JH, and LMH analyzed data;
542 SD and JH wrote the first draft of the manuscript and LMH and TK made substantive revisions; TK and
543 LMH had primary responsibility for final content. All authors read and approved the final manuscript.

544

545 **Acknowledgements**

546 This study was supported by grants from the NIDDK (R01 DK104772) and from the Connors Center for
547 Women's Health and Gender Biology at Brigham and Women's Hospital. We would like to thank Sarah
548 Boukezzi for her contributions to initial aspects of study design, Harlyn Aizley and Florina Haimovici for
549 clinical assessments, Rose Chang for assistance with project coordination. We are grateful to Jill
550 Goldstein, Diego Pizzagalli, and Daniel Dillon with their contributions to R01 DK104772. Work in the
551 Klengel Lab is supported by NICHD R01 HD102974, the Connor Group Kids and Community Partners, and
552 NIA R01 AG070704.

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572 **Tables and Table Legends**

573

574 **Table 1.** Demographic, Trait, and Baseline Variables

575

	HypoMDD (n=13)	HyperMDD (n=8)	p-value	z-value
Sex, N (%)			1.000 ^a	
Female	7 (53.8)	5 (62.5)		
Male	6 (46.2)	3 (27.5)		
Age, M (SD)	30.5 (8.2)	27.6 (6.1)	0.595 ^b	-0.545
BMI, M (SD)	25.5 (3.1)	25.3 (2.0)	0.972 ^b	-0.072
Race, N (%)			0.118 ^c	
White	9 (69.2)	4 (50)		
Black or AA	4 (30.7)	1 (12.5)		
Asian	0	2 (25)		
Other	0 (0)	1 (12.5)		
Ethnicity, N (%)			0.618 ^a	
Hispanic / Latino	2 (25)	2 (25)		
Current Smoking, N (%)	1 (7.7)	0 (0)	1.000 ^a	
BDI, M (SD)	23.7 (6.3)	31.2 (10)	0.025^b	2.24
STAI Trait, M (SD)	55.5 (8.9)	60.9 (8.6)	0.121 ^b	-1.56
DEBQ, M (SD)				
Emotional Eating	2.3 (0.5)	3.2 (0.7)	0.008^b	-2.62
External Eating	3.0 (0.5)	3.6 (0.6)	0.045^b	-2.04
Restrained Eating	2.5 (0.8)	2.9 (0.5)	0.268 ^b	-1.16
Perceived Stress Scale, M (SD)	26.0 (3.3)	23.4 (5.5)	0.185 ^b	-1.38
Breakfast Meal Intake, M (SD)				
PVC Total (kcal)	73.7 (18.1)	85.2 (17.2)	0.064 ^b	1.85
PVC Protein (kcal)	63.8 (25.9)	87.4 (16.3)	0.030^b	2.14
PVC Fat (kcal)	70.2 (27.6)	92.9 (9.6)	0.076 ^b	1.78
PVC Carbohydrates (kcal)	73.7 (18.1)	85.2 (17.2)	0.161 ^b	1.41

576

577

- 578 AA = African American
- 579 BMI = Body Mass Index
- 580 BDI = Beck Depression Inventory
- 581 STAI-T = State Trait Anxiety Inventory - Trait
- 582 DEBQ = Dutch Eating Behavior Questionnaire
- 583 PVC = planned versus consumed
- 584 a = Fisher's Exact Test
- 585 b = Mann-Whitney U Test
- 586 c = Chi Square
- 587 M = mean
- 588 SD = Standard Deviation
- 589 Statistically significant values are indicated by bold font

590 **Table 2.** Hormone responses

591

		No-Stress						Stress					
		Hypophagic MDD	Hyperphagic MDD	Within Subjects (T0-T105)		Between Subjects		Hypophagic MDD	Hyperphagic MDD*	Within Subjects (T0-T105)		Between Subjects	
	Timepoint	M (SD)	M (SD)	Hypophagic MDD	Hyperphagic MDD	p-value	z-value	M (SD)	M (SD)	Hypophagic MDD	Hyperphagic MDD*	p-value	z-value
Cortisol (µg/dL)	T0	15.1 (4.8)	14.8 (6.9)					17.8 (7.9)	13.6 (6.5)				
	T105	10.6 (4.9)	10.4 (5.9)					13.1 (4.7)	10.2 (4.7)				
log2 Cortisol	T0	3.8 (0.5)	3.8 (0.6)	z= -2.71 p=0.006 ^a	z= -2.24 p=0.025 ^a	0.500 ^b	-0.688	4.0 (0.7)	3.7 (0.6)			0.183 ^b	-1.35
	T105	3.2 (0.9)	3.2 (0.7)			0.804 ^b	-0.254	3.6 (0.7)	3.2 (0.7)	z=-2.06 p=0.039 ^a	z=-1.35 p=0.176	0.115 ^b	-1.59
Ghrelin (pg/mL)	T0	782.7 (771.7)	420.6 (195.8)					671.7 (542.7)	392.8 (107.1)				
	T105	654.6 (710.0)	368.3 (117.9)					595.3 (479.7)	332.9 (116.9)				
log2 Ghrelin	T0	9.1 (1.2)	8.5 (0.9)	z=-1.78 p=0.075 ^a	z=-0.42 p=0.674 ^a	0.238 ^b	-1.23	9.1 (1.0)	8.6 (0.4)			0.161 ^b	-1.45
	T105	8.9 (1.1)	8.5 (0.5)			0.210 ^b	-1.30	8.9 (1.0)	8.3 (0.5)	z=-1.22 p=0.221 ^a	z=-1.26 p=0.208	0.140 ^b	-1.52

592

593 M = mean

594 SD = standard deviation

595 a = nonparametric result from the Wilcoxon Signed Ranks test

596 b = nonparametric result from the Mann-Whitney U test

597 *n=7 due to data loss of one subject.

598

599

600

601 **Table 3. Mood Ratings**

		No-Stress						Stress					
		Hypophagic MDD*	Hyperphagic MDD	Within Subjects (T0 - T105)		Between Subjects		Hypophagic MDD	Hyperphagic MDD	Within Subjects (T0 - T105)		Between Subjects	
	Timepoint	M (SD)	M (SD)	Hypophagic MDD*	Hyperphagic MDD	p-value	z-value	M (SD)	M (SD)	Hypophagic MDD	Hyperphagic MDD	p-value	z-value
Sad	T0	35.0 (22.5)	42.8 (22.7)		z=0.676 p=0.49	0.336 ^b	-0.978	47.8 (28.8)	53.6 (24.7)	z=-1.16 p=0.248 ^a	z=-.508 p=0.611 ^a	0.75 ^b	-0.363
	T105	33.3 (17.6)	48.1 (29.5)	z=-1.07 p=0.286 ^a	9 ^a	0.238 ^b	-1.241	38.5 (24.6)	51.9 (22.0)			0.121 ^b	-1.591
Tense	T0	32.7 (20.5)	43.1 (20.0)		z=1.47 p=0.14	0.414 ^b	-0.871	41.2 (32.9)	43.8 (18.6)	z=0.157 p=0.875 ^a	z=2.10 p=0.035 ^a	0.86 ^b	-0.217
	T105	37.9 (22.7)	60.5 (25.7)	z=0.711 p=0.477 ^a	1 ^a	0.047^b	-1.977	42.5 (26.6)	62.5 (18.3)			0.045^b	-2.051

602

603 p-values represent between-group comparisons with the Mann-Whitney U-test

604 M = mean

605 SD = standard deviation

606 * = n=12 for tense ratings due to data loss in one subject

607 a = nonparametric result from the Wilcoxon Signed Ranks test

608 b = nonparametric result from the Mann-Whitney U test

609 Statistically significant p-values are indicated in bold font.

610

611

612

613

614

615

616 **Table 4.** Association between TADA2B expression and other measurements

617

	β (SE)	t-value	p-value
log2Cortisol	-0.014 (0.028)	-0.515	0.607
log2Ghrelin	-0.012 (0.021)	-0.587	0.557
Mood Sad	0.00053 (0.00064)	0.825	0.409
Mood Tense	0.00017 (0.00064)	0.264	0.792
breakfast PVC Total (kcal)	0.0015 (0.0010)	1.526	0.127
breakfast PVC Protein (kcal)	0.00079 (0.00080)	0.982	0.326
breakfast PVC Fat (kcal)	0.0017 (0.00071)	2.335	0.020
breakfast PVC Carb (kcal)	0.00090 (0.0010)	0.001	0.376
DEBQ Emotional Eating	0.0076 (0.041)	1.832	0.085
DEBQ External Eating	0.107 (0.043)	2.480	0.024
DEBQ Restrained Eating	0.070 (0.036)	1.942	0.069

618

619 β = Estimate

620 SE = Standard Error

621 Statistically significant p-values indicated in bold font.

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637 **Table 5.** Association between stress-induced transcripts expression and other measurements

638

	CCDC196			SPATA33		
	β (SE)	t-value	p-value	β (SE)	t-value	p-value
log2Cortisol	0.028 (0.099)	0.279	0.780	-0.54 (0.18)	-3.000	0.0027
log2Ghrelin	-0.15 (0.077)	-1.903	0.057	-0.12 (0.16)	-0.759	0.448
Mood Sad	0.0032 (0.0032)	1.009	0.313	-0.0011 (0.0067)	-0.169	0.866
Mood Tense	0.0059 (0.0031)	1.920	0.055	0.0038 (0.0066)	0.587	0.557
breakfast PVC Total (kcal)	0.0069 (0.0038)	1.800	0.072	0.011 (0.0080)	1.336	0.182
breakfast PVC Protein (kcal)	0.0075 (0.0028)	2.695	0.007	0.012 (0.0059)	2.035	0.042
breakfast PVC Fat (kcal)	0.0036 (0.0031)	1.174	0.240	0.0064 (0.0063)	1.015	0.310
breakfast PVC Carb (kcal)	0.0051 (0.0038)	1.331	0.183	0.0072 (0.0079)	0.906	0.365

639

640

641

642

643

644

645

646

647

648

649

650

651


652

653

654 **Figures and Figure Legends**

655

656 **Figure 1.** Schematic depiction of the Maastricht Acute Stress Task (MAST)



HIT = hand immersion trial
A = Arithmetic

657

658


659

660


661 **Figure 2.** Baseline transcriptional differences at baseline T0. **(A)** TADA2B was found to be differentially
662 expressed between Hyperphagic and Hypophagic MDD at baseline. The expression of TADA2B is
663 elevated in Hyperphagic MDD in comparison to Hypophagic MDD. **(B)** Gene Ontologies related to
664 immune signaling pathways were found to be most significantly enriched using nominally significant
665 differentially expressed genes ($p_{\text{nominal}} < 0.05$).

666

667 **A**



B




668

669 **Figure 3.** Differential transcriptional changes in response to stress at T105. **(A)** SPATA33 was found to be
670 differentially expressed between Hyperphagic and Hypophagic MDD after MAST. The expression of
671 SPATA33 was decreased in Hyperphagic MDD while increasing to Hypophagic MDD. **(B)** CCDC196 was
672 also found to be differentially expressed in response to stress. Conversely to the expression of SPATA33,
673 the expression of CCDC196 increased in Hyperphagic MDD and decreased in Hypophagic MDD. **(C)** 7
674 Gene Ontologies were found to be significantly enriched using nominally significant differentially
675 expressed genes ($p_{\text{nominal}} < 0.05$).

676

677



678

679

680

681 **Supplementary Data in Separate Files**

682

683 **Supplemental Figure 1A**

684 PCA association plot of covariates and calculated PCs at baseline.

685

686 **Supplemental Figure 1B**

687 PCA association plot of covariates and calculated PCs after stress task.

688

689 **Supplemental Figure 2**

690 QQ plots with lambda values for baseline transcriptomic difference comparison.

691

692 **Supplemental Figure 3**

693 QQ plots with lambda values for stress-induced transcriptomic difference comparison.

694

695

696 **Supplement Table 1**

697 Differentially expressed genes at T0

698

699 **Supplement Table 2**

700 Differentially expressed genes at T105

701

702 **Supplement Table 3**

703 Enriched GO terms at T0

704

705 **Supplement Table 4**

706 Enriched GO terms at T105

707

708 **Supplement Table 5**

709 Enriched de Kluvier et al. pathways at T0

710 **References**

711

- 712 1 Simmons, W. K. *et al.* Appetite changes reveal depression subgroups with distinct
713 endocrine, metabolic, and immune states. *Mol Psychiatry* **25**, 1457-1468,
714 doi:10.1038/s41380-018-0093-6 (2020).
- 715 2 Lamers, F. *et al.* Stability and transitions of depressive subtypes over a 2-year follow-up.
716 *Psychol Med* **42**, 2083-2093, doi:10.1017/s0033291712000141 (2012).
- 717 3 Andréasson, A., Arborelius, L., Erlanson-Albertsson, C. & Lekander, M. A putative role for
718 cytokines in the impaired appetite in depression. *Brain, Behavior, and Immunity* **21**, 147-
719 152, doi:<https://doi.org/10.1016/j.bbi.2006.08.002> (2007).
- 720 4 Cerit, H. *et al.* Divergent associations between ghrelin and neural responsivity to
721 palatable food in hyperphagic and hypophagic depression. *J Affect Disord* **242**, 29-38,
722 doi:10.1016/j.jad.2018.07.088 (2019).
- 723 5 Simmons, W. K. *et al.* Depression-Related Increases and Decreases in Appetite:
724 Dissociable Patterns of Aberrant Activity in Reward and Interoceptive Neurocircuitry.
725 *Am J Psychiatry* **173**, 418-428, doi:10.1176/appi.ajp.2015.15020162 (2016).
- 726 6 Kroemer, N. B. *et al.* Functional Connectivity of the Nucleus Accumbens and Changes in
727 Appetite in Patients With Depression. *JAMA Psychiatry* **79**, 993-1003,
728 doi:10.1001/jamapsychiatry.2022.2464 (2022).
- 729 7 Piccolo, M. *et al.* Alterations in resting-state functional activity and connectivity for
730 major depressive disorder appetite and weight disturbance phenotypes. *Psychol Med*, 1-
731 11, doi:10.1017/s0033291722001398 (2022).
- 732 8 Cosgrove, K. T. *et al.* Appetite change profiles in depression exhibit differential
733 relationships between systemic inflammation and activity in reward and interoceptive
734 neurocircuitry. *Brain Behav Immun* **83**, 163-171, doi:10.1016/j.bbi.2019.10.006 (2020).
- 735 9 Milaneschi, Y. *et al.* Genetic Association of Major Depression With Atypical Features and
736 Obesity-Related Immunometabolic Dysregulations. *JAMA Psychiatry* **74**, 1214-1225,
737 doi:10.1001/jamapsychiatry.2017.3016 (2017).

- 738 10 de Kluiver, H., Jansen, R., Milaneschi, Y. & Penninx, B. W. J. H. Involvement of
739 inflammatory gene expression pathways in depressed patients with hyperphagia.
740 *Translational Psychiatry* **9**, 193, doi:10.1038/s41398-019-0528-0 (2019).
- 741 11 Spitzer, R. L., Williams, J. B., Gibbon, M. & First, M. B. The Structured Clinical Interview
742 for DSM-III-R (SCID). I: History, rationale, and description. *Arch Gen Psychiatry* **49**, 624-
743 629, doi:10.1001/archpsyc.1992.01820080032005 (1992).
- 744 12 Smeets, T. *et al.* Introducing the Maastricht Acute Stress Test (MAST): a quick and non-
745 invasive approach to elicit robust autonomic and glucocorticoid stress responses.
746 *Psychoneuroendocrinology* **37**, 1998-2008, doi:10.1016/j.psyneuen.2012.04.012 (2012).
- 747 13 Beck, A. T., Steer, R. A. & Brown, G. Beck depression inventory—II. *Psychological*
748 *assessment* (1996).
- 749 14 Whybrow, S., Stephen, J. R. & Stubbs, R. J. The evaluation of an electronic visual
750 analogue scale system for appetite and mood. *Eur J Clin Nutr* **60**, 558-560,
751 doi:10.1038/sj.ejcn.1602342 (2006).
- 752 15 Spielberger, C. D. Manual for the state-trait anxiety, inventory. *Consulting Psychologist*
753 (1970).
- 754 16 Cohen, S., Kamarck, T. & Mermelstein, R. A global measure of perceived stress. *Journal*
755 *of health and social behavior*, 385-396 (1983).
- 756 17 van Strien, T., Frijters, J. E. R., Bergers, G. P. A. & Defares, P. B. The Dutch Eating
757 Behavior Questionnaire (DEBQ) for assessment of restrained, emotional, and external
758 eating behavior. *International Journal of Eating Disorders* **5**, 295-315,
759 doi:[https://doi.org/10.1002/1098-108X\(198602\)5:2<295::AID-](https://doi.org/10.1002/1098-108X(198602)5:2<295::AID-EAT2260050209>3.0.CO;2-T)
760 [EAT2260050209>3.0.CO;2-T](https://doi.org/10.1002/1098-108X(198602)5:2<295::AID-EAT2260050209>3.0.CO;2-T) (1986).
- 761 18 Harris, J. A. & Benedict, F. G. A Biometric Study of Human Basal Metabolism. *Proc Natl*
762 *Acad Sci U S A* **4**, 370-373, doi:10.1073/pnas.4.12.370 (1918).
- 763 19 bcbio/bcbio-nextgen v. v.1.2.8 (Zenodo, 2021).
- 764 20 Dobin, A. *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15-21,
765 doi:10.1093/bioinformatics/bts635 (2013).

- 766 21 Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and
767 bias-aware quantification of transcript expression. *Nature Methods* **14**, 417-419,
768 doi:10.1038/nmeth.4197 (2017).
- 769 22 Ritchie, M. E. *et al.* limma powers differential expression analyses for RNA-sequencing
770 and microarray studies. *Nucleic Acids Res* **43**, e47, doi:10.1093/nar/gkv007 (2015).
- 771 23 van Iterson, M., van Zwet, E. W., Heijmans, B. T. & the, B. C. Controlling bias and
772 inflation in epigenome- and transcriptome-wide association studies using the empirical
773 null distribution. *Genome Biology* **18**, 19, doi:10.1186/s13059-016-1131-9 (2017).
- 774 24 Ashburner, M. *et al.* Gene Ontology: tool for the unification of biology. *Nat Genet* **25**,
775 25-29, doi:10.1038/75556 (2000).
- 776 25 Gene Ontology, C. The Gene Ontology resource: enriching a GOld mine. *Nucleic Acids*
777 *Research* **49**, D325-D334, doi:10.1093/nar/gkaa1113 (2021).
- 778 26 Subramanian, A. *et al.* Gene set enrichment analysis: A knowledge-based approach for
779 interpreting genome-wide expression profiles. *Proceedings of the National Academy of*
780 *Sciences* **102**, 15545-15550, doi:10.1073/pnas.0506580102 (2005).
- 781 27 Liberzon, A. *et al.* The Molecular Signatures Database (MSigDB) hallmark gene set
782 collection. *Cell Syst* **1**, 417-425, doi:10.1016/j.cels.2015.12.004 (2015).
- 783 28 Puzhko, S. *et al.* Excess body weight as a predictor of response to treatment with
784 antidepressants in patients with depressive disorder. *J Affect Disord* **267**, 153-170,
785 doi:10.1016/j.jad.2020.01.113 (2020).
- 786 29 Milaneschi, Y., Simmons, W. K., van Rossum, E. F. C. & Penninx, B. W. Depression and
787 obesity: evidence of shared biological mechanisms. *Mol Psychiatry* **24**, 18-33,
788 doi:10.1038/s41380-018-0017-5 (2019).
- 789 30 Barlev, N. A. *et al.* A novel human Ada2 homologue functions with Gcn5 or Brg1 to
790 coactivate transcription. *Mol Cell Biol* **23**, 6944-6957, doi:10.1128/MCB.23.19.6944-
791 6957.2003 (2003).
- 792 31 Naxerova, K. *et al.* Integrated loss- and gain-of-function screens define a core network
793 governing human embryonic stem cell behavior. *Genes Dev.* **35**, 1527-1547,
794 doi:10.1101/gad.349048.121 (2021).

- 795 32 Lowe, J. K., Werling, D. M., Constantino, J. N., Cantor, R. M. & Geschwind, D. H.
796 Quantitative linkage analysis to the autism endophenotype social responsiveness
797 identifies genome-wide significant linkage to two regions on chromosome 8. *The*
798 *American journal of psychiatry* **172**, 266-275, doi:10.1176/appi.ajp.2014.14050576
799 (2015).
- 800 33 Juruena, M. F., Bocharova, M., Agustini, B. & Young, A. H. Atypical depression and non-
801 atypical depression: Is HPA axis function a biomarker? A systematic review. *J Affect*
802 *Disord* **233**, 45-67, doi:10.1016/j.jad.2017.09.052 (2018).
- 803 34 Priyanka, P. P. & Yenugu, S. Coiled-Coil Domain-Containing (CCDC) Proteins: Functional
804 Roles in General and Male Reproductive Physiology. *Reprod. Sci.* **28**, 2725-2734,
805 doi:10.1007/s43032-021-00595-2 (2021).
- 806 35 Jiang, C. *et al.* LINC00238 inhibits hepatic carcinoma progression by activating
807 TMEM106C-mediated apoptosis pathway. *Molecular Medicine Reports* **24**, 1-10,
808 doi:10.3892/mmr.2021.12397 (2021).
- 809 36 Qian, H.-G. *et al.* Long non-coding RNA LINC00238 suppresses the malignant phenotype
810 of liver cancer by sponging miR-522. *Molecular Medicine Reports* **25**, 71,
811 doi:10.3892/mmr.2022.12587 (2022).
- 812 37 Miyata, H. *et al.* SPATA33 localizes calcineurin to the mitochondria and regulates sperm
813 motility in mice. *Proceedings of the National Academy of Sciences* **118**, e2106673118,
814 doi:10.1073/pnas.2106673118 (2021).
- 815 38 Zhang, Y. *et al.* SPATA33 is an autophagy mediator for cargo selectivity in germline
816 mitophagy. *Cell Death Differ* **28**, 1076-1090, doi:10.1038/s41418-020-00638-2 (2021).
- 817 39 Fang, S. *et al.* Functional annotation of melanoma risk loci identifies novel susceptibility
818 genes. *Carcinogenesis* **41**, 452-457, doi:10.1093/carcin/bgz173 (2020).
- 819 40 Liu, X. *et al.* Calorie restriction and calorie dilution have different impacts on body fat,
820 metabolism, behavior, and hypothalamic gene expression. *Cell Reports* **39**, 110835,
821 doi:10.1016/j.celrep.2022.110835 (2022).
- 822
- 823